Please wait
false 0001757898 0001757898 2026-07-31 2026-07-31 0001757898 us-gaap:CommonStockMember 2026-07-31 2026-07-31 0001757898 ste:STETwo700SeniorNotesDue2031Member 2026-07-31 2026-07-31 0001757898 ste:Two700SeniorNotesDue2051Member 2026-07-31 2026-07-31
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2026

 

 

STERIS plc

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   001-38848   98-1455064
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

70 Sir John Rogerson’s Quay
Dublin 2, Ireland D02 R296
(Address of Principal Executive Offices)

+353 1 232 2000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Ordinary Shares, $0.001 par value   STE   New York Stock Exchange
2.700% Senior Notes due 2031   STE/31   New York Stock Exchange
3.750% Senior Notes due 2051   STE/51   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


ITEM 5.07.

Submission of Matters to a Vote of Security Holders.

At the 2026 Annual General Meeting of Shareholders (“Meeting”) of STERIS plc (the “Company”) held on July 31, 2026, shareholders voted on the matters specified below, with the final voting results as specified. According to the final report of the inspector of election, there were 97,457,680 ordinary shares of the Company (the “Ordinary Shares”) outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 89,909,204 Ordinary Shares or 92.25% of the outstanding Ordinary Shares of the Company on the record date, constituting a quorum. Effective as of the completion of the Meeting, the size of the board of directors of the Company (the “Board”) was reduced to nine members.

 

1.

The shareholders elected the nominees named below to the Board, each for a one-year term, and the results of the vote were as follows:

 

Nominee

   Votes for      Votes
against
     Abstentions      Broker
non-votes
 

Dr. Esther M. Alegria

     83,736,807        2,489,416        69,805        3,613,176  

Pierre Boulud

     85,609,905        660,872        25,251        3,613,176  

Daniel A. Carestio

     85,666,543        608,056        21,429        3,613,176  

Cynthia L. Feldmann

     74,792,537        11,102,333        401,158        3,613,176  

Christopher S. Holland

     79,153,223        7,117,534        25,271        3,613,176  

Paul E. Martin

     84,800,040        1,473,359        22,629        3,613,176  

Dr. Nirav R. Shah

     84,860,439        1,410,341        25,248        3,613,176  

Louis A. Shapiro

     85,688,682        583,125        24,221        3,613,176  

Dr. Mohsen M. Sohi

     78,870,373        7,215,557        210,098        3,613,176  

 

2.

The shareholders approved the proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2027 by the following votes:

 

Votes for      82,976,444  
Votes against      6,914,777  
Abstentions      17,983  

 

3.

The shareholders approved the proposal to appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next Annual General Meeting by the following votes:

 

Votes for      82,815,679  
Votes against      7,075,177  
Abstentions      18,348  

 

4.

The shareholders approved the proposal to authorize the Board of the Company or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law by the following votes:

 

Votes for      88,268,114  
Votes against      1,616,190  
Abstentions      24,900  

 

5.

The shareholders approved the proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 11, 2026, by the following votes:

 

Votes for      77,639,271  
Votes against      8,493,021  
Abstentions      163,736  
Broker non-votes      3,613,176  

 


6.

The shareholders approved the proposal to the renewal of the Board’s authority to issue authorized but unissued shares under Irish law, by the following votes:

 

Votes for      89,209,571  
Votes against      681,087  
Abstentions      18,546  

 

7.

The shareholders approved the proposal to approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash, by the following votes:

 

Votes for      86,256,858  
Votes against      3,483,603  
Abstentions      168,743  

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STERIS plc
By   

/s/ J. Adam Zangerle

  J. Adam Zangerle
  Senior Vice President, General Counsel & Company Secretary

Dated: August 6, 2026